OnCusp is a clinical stage biopharmaceutical company developing therapeutics for oncology indications.

OnCusp Therapeutics’s management team specializes in identifying mature technologies for in-licensing and clinical trial execution. Their lead program is a highly promising antibody drug conjugate (ADC) tested in gynecological, liver, and kidney cancers with best-in-class potential. Other assets in the pipeline include a small molecule targeted agent and a bi-specific antibody.